文献速递流行病学与生物统计真实世界研究与卫生经济新药、器械与细胞基因治疗研发

西非和中非大规模季节性疟疾化学预防的有效性:一项观察性研究

Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.
PubMed 文献 · Lancet · 2020-01-01

ACCESS-SMC项目在布基纳法索、乍得、冈比亚、几内亚、马里、尼日尔和尼日利亚七国,于2015和2016年对5岁以下儿童每月实施SMC。

要点

  • 高传播期疟疾住院死亡在布基纳法索和冈比亚明显下降。
  • 严重药物不良反应罕见,但需监测磺胺多辛-乙胺嘧啶耐药选择。

核心结论

  • 大规模SMC可有效预防疟疾发病和死亡。
  • 严重药物不良反应报告罕见。
  • 磺胺多辛-乙胺嘧啶和阿莫地喹耐药标志仍不常见,但磺胺多辛-乙胺嘧啶耐药有选择增加,需仔细监测。

研究设计与样本

  • 观察性研究,在布基纳法索、乍得、冈比亚、几内亚、马里、尼日尔和尼日利亚七国开展。
  • 2015和2016年每年对5岁以下儿童实施4个月SMC,由社区卫生工作者每月入户给药。
  • 通过药房警戒、分子标志调查、病例对照研究和卫生管理信息系统评估效果、安全性、耐药、成本和成本效果。

关键数值与推荐

  • SMC每月给药一次,每年实施4个月,对象为5岁以下儿童。
  • 2015-16年共779份个体安全性报告,36例严重药物不良反应(1例皮疹、2例发热、31例胃肠道紊乱、1例锥体外系综合征、1例Quincke水肿),无严重皮肤反应(Stevens-Johnson或Lyell综合征)。

临床怎么用

  • 在疟疾高传播季节对5岁以下儿童按月实施SMC可显著降低发病和死亡。
  • 入户逐户给药可实现较高覆盖率,但需关注全程完成率。
  • 应持续监测磺胺多辛-乙胺嘧啶和阿莫地喹耐药标志。

局限性

  • 为观察性研究,非随机对照设计。
  • 覆盖率存在地区差异,部分地区通过入户活动持续实现高覆盖率。
  • 耐药标志监测基于社区调查,需长期跟踪。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seasonal malaria chemoprevention (SMC) aims to prevent malaria in children during the high malaria transmission season. The Achieving Catalytic Expansion of SMC in the Sahel (ACCESS-SMC) project sought to remove barriers to the scale-up of SMC in seven countries in 2015 and 2016. We evaluated the project, including coverage, effectiveness of the intervention, safety, feasibility, drug resistance, and cost-effectiveness. METHODS: For this observational study, we collected data on the delivery, effectiveness, safety, influence on drug resistance, costs of delivery, impact on malaria incidence and mortality, and cost-effectiveness of SMC, during its administration for 4 months each year (2015 and 2016) to children younger than 5 years, in Burkina Faso, Chad, The Gambia, Guinea, Mali, Niger, and Nigeria. SMC was administered monthly by community health workers who visited door-to-door. Drug administration was monitored via tally sheets and via household cluster-sample coverage surveys. Pharmacovigilance was based on targeted spontaneous reporting and monitoring systems were strengthened. Molecular markers of resistance to sulfadoxine-pyrimethamine and amodiaquine in the general population before and 2 years after SMC introduction was assessed from community surveys. Effectiveness of monthly SMC treatments was measured in case-control studies that compared receipt of SMC between patients with confirmed malaria and neighbourhood-matched community controls eligible to receive SMC. Impact on incidence and mortality was assessed from confirmed outpatient cases, hospital admissions, and deaths associated with malaria, as reported in national health management information systems in Burkina Faso and The Gambia, and from data from selected outpatient facilities (all countries). Provider costs of SMC were estimated from financial costs, costs of health-care staff time, and volunteer opportunity costs, and cost-effectiveness ratios were calculated as the total cost of SMC in each country divided by the predicted number of cases averted. FINDINGS: 12 467 933 monthly SMC treatments were administered in 2015 to a target population of 3 650 455 children, and 25 117 480 were administered in 2016 to a target population of 7 551 491. In 2015, among eligible children, mean coverage per month was 76·4% (95% CI 74·0-78·8), and 54·5% children (95% CI 50·4-58·7) received all four treatments. Similar coverage was achieved in 2016 (74·8% [72·2-77·3] treated per month and 53·0% [48·5-57·4] treated four times). In 779 individual case safety reports over 2015-16, 36 serious adverse drug reactions were reported (one child with rash, two with fever, 31 with gastrointestinal disorders, one with extrapyramidal syndrome, and one with Quincke's oedema). No cases of severe skin reactions (Stevens-Johnson or Lyell syndrome) were reported. SMC treatment was associated with a protective effectiveness of 88·2% (95% CI 78·7-93·4) over 28 days in case-control studies (2185 cases of confirmed malaria and 4370 controls). In Burkina Faso and The Gambia, implementation of SMC was associated with reductions in the number of malaria deaths in hospital during the high transmission period, of 42·4% (95% CI 5·9 to 64·7) in Burkina Faso and 56·6% (28·9 to 73·5) in The Gambia. Over 2015-16, the estimated reduction in confirmed malaria cases at outpatient clinics during the high transmission period in the seven countries ranged from 25·5% (95% CI 6·1 to 40·9) in Nigeria to 55·2% (42·0 to 65·3) in The Gambia. Molecular markers of resistance occurred at low frequencies. In individuals aged 10-30 years without SMC, the combined mutations associated with resistance to amodiaquine (pfcrt CVIET haplotype and pfmdr1 mutations [86Tyr and 184Tyr]) had a prevalence of 0·7% (95% CI 0·4-1·2) in 2016 and 0·4% (0·1-0·8) in 2018 (prevalence ratio 0·5 [95% CI 0·2-1·2]), and the quintuple mutation associated with resistance to sulfadoxine-pyrimethamine (triple mutation in pfdhfr and pfdhps mutations [437Gly and 540Glu]) had a prevalence of 0·2% (0·1-0·5) in 2016 and 1·0% (0·6-1·6) in 2018 (prevalence ratio 4·8 [1·7-13·7]). The weighted average economic cost of administering four monthly SMC treatments was US$3·63 per child. INTERPRETATION: SMC at scale was effective in preventing morbidity and mortality from malaria. Serious adverse reactions were rarely reported. Coverage varied, with some areas consistently achieving high levels via door-to-door campaigns. Markers of resistance to sulfadoxine-pyrimethamine and amodiaquine remained uncommon, but with some selection for resistance to sulfadoxine-pyrimethamine, and the situation needs to be carefully monitored. These findings should support efforts to ensure high levels of SMC coverage in west and central Africa. FUNDING: Unitaid.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet. 2020. PMID: 33278936. doi:10.1016/S0140-6736(20)32227-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。